Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Black people with obesity are less likely to get weight-loss surgery than others.Black people are just as likely to d ...

Heart disease remains the number one killer worldwide, outstripping all other causes of death as key risk factors continue to ...

Heart disease remains the leading cause of death in the U.S.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Highlights: According to the American Heart Association's 2025 Heart Disease and Stroke Statistics Update, heart disease ...

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to lower their weight compared with whites, new research suggests. The ...

Men were less likely than women to have weight-loss surgery, and that gap has widened over time, while Black patients were ...

People tend to get overweight instead, and now obesity is considered a disease that ... with Novo Nordisk's Ozempic and Wegovy lead. The race heats up as Eli Lily (NYSE:LLY)'s Zepbound gives ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

Skeletal muscle fat infiltration (IMAT) is linked to coronary microvascular dysfunction and increased cardiovascular risk, ...

The lucrative market of weight loss industry has succeeded appeal 34 companies to compete in GLP-1 receptor agonists which is dubbed as the life-changing drugs for obesity with Novo Nordisk's Ozempic ...